National Health Investors, Inc. rose 1.10% intraday, with the company's stock performance aligning with the positive outlook in the biotech sector. The biotech sector is experiencing a pivotal phase driven by scientific breakthroughs, accelerated regulatory approvals, and a surge in strategic dealmaking. The Nasdaq Biotechnology Index has posted strong gains, signaling renewed investor confidence. The FDA is clearing a record number of novel therapies, while global mergers and acquisitions have climbed past $105 billion, a seven percent increase from last year.
Comments
No comments yet